COVID-19 Vaccination in Cancer Patients: A Comprehensive Review

Strategic Insights -

Cancer patients have been highly vulnerable to COVID-19 infection due to their immunosuppressive status. Recent research has investigated the effectiveness of COVID-19 vaccines in this population, highlighting both the benefits and challenges. A comprehensive review of clinical trials and real-world data has shown that COVID-19 vaccines are generally well-tolerated and efficacious in patients with cancer, although the immunogenicity is often weakened in hematologic malignancies. Booster doses improve immunogenicity and seroresponse against SARS-CoV-2 variants, emphasizing the importance of personalized booster approaches.

Key Takeaways:

  • COVID-19 vaccination is a practical and valuable approach for alleviating risk and improving outcomes in patients with cancer, according to researchers at Taibah University.
  • Several approved COVID-19 vaccines were assessed for their effectiveness in the general population, but initially, cancer patients were excluded from large landmark trials.
  • Accumulated evidence from multiple clinical trials and real-world data suggests that COVID-19 vaccines are generally well-tolerated, safe, and efficacious in patients with both solid and hematologic types of cancer.
  • Vaccine-induced humoral response and cellular response are often weakened in cancer patients, especially those with hematologic malignancies, compared to those of non-cancerous individuals.
  • The immunogenicity in cancer patients improves significantly with booster doses, and seroresponse against SARS-CoV-2 variants increases with additional booster doses.
  • Despite vaccination, cancer patients develop breakthrough infections, which are associated with hospitalization and higher mortality compared to the general population.

Statistics:

  • 2020: COVID-19 led to a worldwide pandemic.
  • 2025: Research concluded that COVID-19 vaccination is a practical and valuable approach for alleviating risk and improving outcomes in patients with cancer.
  • 33%: Of cancer patients experienced moderate adverse reactions and up to 5% experienced rare severe reactions, including immune-related adverse events, thrombotic events, and anaphylaxis.
  • 92%: Of patients with cancer demonstrated durable immune responses after vaccination.

Sources:

  • Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects. Supportive Care in Cancer, 2025;33(8):753. (Springer - www.springer.com; Supportive Care in Cancer - www.springerlink.com/content/0941-4355/)
  • National Institute of Health (NIH)
  • Centers for Disease Control and Prevention (CDC)